A substantial advancement in glucose care is emerging with the approval of tirzepatide at a dosage of 45mg. This updated offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and https://ztndz.com/story28074786/revolutionary-introduction-tirzepatide-strength-for-glucose-regulation